

Annual reports in medicinal chemistry.

Macor, John E.

Elsevier/AP,

2009

Electronic books

Monografía

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.* Covers findings related to cardiovascular, inflammation, and pulmonary diseases* Examines issues in oncology, from mTor inhibitors to drug targets* Incorporates upto-date information on drug design and discovery, including delivery to market

https://rebiunoda.pro.baratznet.cloud:38443/Opac Discovery/public/catalog/detail/b2FpOmNlbGVicmF0aW9uOmVzLmJhcmF0ei5yZW4vMTk2NzI1MDU

Título: Annual reports in medicinal chemistry. Volume 44 electronic resource] sponsored by the Division of Medicinal Chemistry of the American Chemical Society; editor-in-chief, John E. Macor

Editorial: Amsterdam Boston Elsevier/AP 2009

Descripción física: 1 online resource (723 p.)

Mención de serie: Annual reports in medicinal chemistry v. 44

Nota general: Description based upon print version of record

Bibliografía: Includes bibliographical references and index

Contenido: Front cover; Annual Reports in Medicinal Chemistry; Copyright page; Contents; Contributors; Preface; Part I: Central Nervous System Diseases; Chapter 1. Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease; 1. Introduction; 2. Etiology of Alzheimer's Disease; 3. Principal Functions of GSK-3; 4. Additional Neuroprotective Indications for GSK-3 Inhibition; 5. Selective Functional Inhibition of GSK-3; 6. GSK-3 Isoforms; 7. SK-3 Crystal Structures; 8. Challenges in the Development of Effective GSK-3 Inhibitors 9. Advances in GSK-3 Inhibitors10. Conclusion; References; Chapter 2. Advancements in the Development of Nitric Oxide Synthase Inhibitors; 1. Introduction; 2. NOS - Structure and Function; 3. Selective NOS Inhibitors; 4. Clinical Findings with NOS Inhibitors; 5. Future Directions - Dual Action NOS Inhibitors; 6. Conclusions; References; Chapter 3. Small-Molecule Protein-Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions; 1. Introduction; 2. Abeta Aggregation and Oligomers in Alzheimer's Disease 3. Tau Aggregation in Alzheimer's Disease4. alpha-Synuclein Aggregation in Parkinson's Disease; 5. Conclusion; References; Chapter 4. Case History: Chantixtrade/Champixtrade (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial

Agonist as a Smoking Cessation Aid; 1. Introduction; 2. Partial Agonists at Nicotinic ACh Receptors; 3. The Search for Partial Agonists: Cytisine as a Key Starting Point; 4. Semi-Synthetic Analogs of Cytisine; 5. Cytisine Synthesis and Early Template Expansion; 6. Discovery of the Bicyclic Benzazepine Core; 7. Fused Bicyclic Benzazepines 8. In vivo Efficacy of Partial Agonists9. Properties of Varenicline; 10. Clinical Studies; 11. Conclusions; References; Part II: Cardiovascular and Metabolic Diseases; Chapter 5. Case History on Tekturnareg /Rasilezreg (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension; 1. Introduction; 2. Rationale for the Use of Direct Renin Inhibitors; 3. Pre-Clinical Models to Study Direct Renin Inhibitors; 4. Medicinal Chemistry Evolution - The Early Renin Inhibitor Program at Ciba-Geigy; 5. First Convergent and Scalable Synthesis Development 6. Pre-Clinical Properties of Aliskiren7. Effects of Aliskiren in Disease Models; 8. Clinical Studies with Aliskiren; 9. Conclusions; References; Chapter 6. Advances in Vasopressin Receptor Agonists and Antagonists; 1. Introduction; 2. V1a Receptor Antagonists; 3. V1b Receptor Antagonists; 4. V2 Receptor Agonists; 5. V2 Receptor Antagonists; 6. Dual V1a-V2 Receptor Antagonists; 7. Summary; References; Chapter 7. The Emergence of GPR119 Agonists as Anti-Diabetic Agents; 1. Introduction; 2. Discovery and Characteristics of GPR119; 3. The Biology of GPR119 4. GPR119 Agonists: Medicinal Chemistry

Lengua: English

ISBN: 1-282-38080-X 9786612380808 0-08-091214-1

Materia: Central nervous system- Diseases Cardiovascular system- Diseases Metabolism- Disorders

Autores: Macor, John Eugene

Entidades: American Chemical Society. Division of Medicinal Chemistry

Enlace a serie principal: Annual reports in medicinal chemistry (CKB)954926957872 (DLC)2005215188

(OCoLC)60625597 1557-8437

Enlace a formato físico adicional: 0-12-374766-X

Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- informa@baratz.es